- Home
- ARR vs VRDN Comparison
ARR vs VRDN Comparison
Compare ARR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- VRDN
- Stock Information
- Founded
- ARR 2008
- VRDN 2006
- Country
- ARR United States
- VRDN United States
- Employees
- ARR N/A
- VRDN N/A
- Industry
- ARR Real Estate Investment Trusts
- VRDN Medical Specialities
- Sector
- ARR Real Estate
- VRDN Health Care
- Exchange
- ARR Nasdaq
- VRDN Nasdaq
- Market Cap
- ARR 1.8B
- VRDN 1.6B
- IPO Year
- ARR N/A
- VRDN N/A
- Fundamental
- Price
- ARR $15.77
- VRDN $24.41
- Analyst Decision
- ARR Buy
- VRDN Strong Buy
- Analyst Count
- ARR 4
- VRDN 10
- Target Price
- ARR $15.50
- VRDN $36.33
- AVG Volume (30 Days)
- ARR 3.1M
- VRDN 828.9K
- Earning Date
- ARR 10-22-2025
- VRDN 11-11-2025
- Dividend Yield
- ARR 18.39%
- VRDN N/A
- EPS Growth
- ARR N/A
- VRDN N/A
- EPS
- ARR N/A
- VRDN N/A
- Revenue
- ARR $20,589,000.00
- VRDN $305,000.00
- Revenue This Year
- ARR $350.86
- VRDN N/A
- Revenue Next Year
- ARR $54.46
- VRDN $34,044.63
- P/E Ratio
- ARR N/A
- VRDN N/A
- Revenue Growth
- ARR N/A
- VRDN 5.90
- 52 Week Low
- ARR $13.18
- VRDN $9.90
- 52 Week High
- ARR $20.39
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- ARR 59.58
- VRDN 71.75
- Support Level
- ARR $15.32
- VRDN $20.71
- Resistance Level
- ARR $15.75
- VRDN $22.37
- Average True Range (ATR)
- ARR 0.31
- VRDN 1.04
- MACD
- ARR 0.04
- VRDN 0.24
- Stochastic Oscillator
- ARR 77.79
- VRDN 86.31
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).